<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126201">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02086474</url>
  </required_header>
  <id_info>
    <org_study_id>INF-2014</org_study_id>
    <nct_id>NCT02086474</nct_id>
  </id_info>
  <brief_title>Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients</brief_title>
  <official_title>Daily Activity Quantification and Gait Pattern Analysis Before and After Intra-articular Injection of Viscosupplement Among Hip Osteoarthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the changes in daily physical activity and gait
      pattern, following a viscosupplement injection among a population who is suffering from hip
      osteoarthritis. A kinetic and kinematic gait analysis, an Actigraph activity monitor, a
      functional Timed-Stair-Test and two questionnaires (Medical Outcome Study Short-Form36
      (MOS-SF36), Hip disability and Osteoarthritis Outcome Score (HOOS)) about how the pathology
      affects the quality of life, will be use.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in hip flexion-extension range of motion</measure>
    <time_frame>Change from Baseline at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subtraction between maximum and minimum flexion measured with motion capture system during gait</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in daily physical activity</measure>
    <time_frame>Change from Baseline at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intensity and duration of the daily physical activity measured with pedometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hip pain</measure>
    <time_frame>change from Baseline at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaires HOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Change from Baseline at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaires: MOS-SF36 and HOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking cadence</measure>
    <time_frame>Change from Baseline at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured during 3D gait analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hyaluronan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one Marcain extra-capsular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronan</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Hyaluronan</arm_group_label>
    <other_name>Hyaluronan acid : Neovisc®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Extra-capsular injection</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>Bupivacaine: Marcaine®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  From 45 years old to 65 years old

          -  Clinically symptomatic moderate or severe hip osteoarthritis (Tönnis Grade II to III)

          -  Capacity to keep steady upright position and walking during 15 minutes

          -  Body mass index &lt; 40kg/m2

        Exclusion Criteria:

          -  Bilateral hip osteoarthritis

          -  No broken hip or leg during the last 12 months

          -  Bone necrosis

          -  Rheumatoid arthritis, articular chondrocalcinosis, metabolic bone disease, psoriasis,
             gout, active infection

          -  Per os corticosteroid treatment

          -  Corticosteroid injection &lt; 3 months

          -  Viscosupplement injection &lt; 6 months

          -  Hypersensitivity to hyaluronic acid products

          -  Planed surgery during study duration

          -  Physical or mental disability to fill in questionnaires and/or to participate to
             follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Cantin-Warren, B.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Étienne L. Belzile, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Corbeil, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie Turmel, RN</last_name>
    <phone>418-524-4444</phone>
    <phone_ext>16055</phone_ext>
    <email>Sylvie.Turmel@mail.chuq.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pavillon de l'Éducation Physique et des Sports - Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Cantin-Warren, B.Sc.</last_name>
      <phone>518-656-2131</phone>
      <phone_ext>4920</phone_ext>
      <email>antoine.cantin-warren.1@ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Antoine Cantin-Warren, B.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Philippe Corbeil</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
